These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 29786791)
1. Protocols for Studies on TMPRSS2/ERG in Prostate Cancer. Pakula H; Linn DE; Schmidt DR; Van Gorsel M; Vander Heiden MG; Li Z Methods Mol Biol; 2018; 1786():131-151. PubMed ID: 29786791 [TBL] [Abstract][Full Text] [Related]
2. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models. Linn DE; Bronson RT; Li Z PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911 [TBL] [Abstract][Full Text] [Related]
3. Retention of Interstitial Genes between Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096 [No Abstract] [Full Text] [Related]
4. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Furusato B; Gao CL; Ravindranath L; Chen Y; Cullen J; McLeod DG; Dobi A; Srivastava S; Petrovics G; Sesterhenn IA Mod Pathol; 2008 Feb; 21(2):67-75. PubMed ID: 18065961 [TBL] [Abstract][Full Text] [Related]
5. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102 [TBL] [Abstract][Full Text] [Related]
6. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259 [TBL] [Abstract][Full Text] [Related]
7. Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer. Thangapazham R; Saenz F; Katta S; Mohamed AA; Tan SH; Petrovics G; Srivastava S; Dobi A BMC Cancer; 2014 Jan; 14():16. PubMed ID: 24418414 [TBL] [Abstract][Full Text] [Related]
8. Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression. Linn DE; Penney KL; Bronson RT; Mucci LA; Li Z Cancer Res; 2016 Apr; 76(7):1869-81. PubMed ID: 26880803 [TBL] [Abstract][Full Text] [Related]
9. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Winnes M; Lissbrant E; Damber JE; Stenman G Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040 [TBL] [Abstract][Full Text] [Related]
10. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer. Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739 [TBL] [Abstract][Full Text] [Related]
11. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Tomlins SA; Laxman B; Varambally S; Cao X; Yu J; Helgeson BE; Cao Q; Prensner JR; Rubin MA; Shah RB; Mehra R; Chinnaiyan AM Neoplasia; 2008 Feb; 10(2):177-88. PubMed ID: 18283340 [TBL] [Abstract][Full Text] [Related]
12. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302 [TBL] [Abstract][Full Text] [Related]
13. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues. Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455 [TBL] [Abstract][Full Text] [Related]
14. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979 [TBL] [Abstract][Full Text] [Related]
15. Micro-RNA-204 Participates in TMPRSS2/ERG Regulation and Androgen Receptor Reprogramming in Prostate Cancer. Todorova K; Metodiev MV; Metodieva G; Mincheff M; Fernández N; Hayrabedyan S Horm Cancer; 2017 Feb; 8(1):28-48. PubMed ID: 28050800 [TBL] [Abstract][Full Text] [Related]
16. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. Setlur SR; Mertz KD; Hoshida Y; Demichelis F; Lupien M; Perner S; Sboner A; Pawitan Y; Andrén O; Johnson LA; Tang J; Adami HO; Calza S; Chinnaiyan AM; Rhodes D; Tomlins S; Fall K; Mucci LA; Kantoff PW; Stampfer MJ; Andersson SO; Varenhorst E; Johansson JE; Brown M; Golub TR; Rubin MA J Natl Cancer Inst; 2008 Jun; 100(11):815-25. PubMed ID: 18505969 [TBL] [Abstract][Full Text] [Related]
17. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Sandoval GJ; Pulice JL; Pakula H; Schenone M; Takeda DY; Pop M; Boulay G; Williamson KE; McBride MJ; Pan J; St Pierre R; Hartman E; Garraway LA; Carr SA; Rivera MN; Li Z; Ronco L; Hahn WC; Kadoch C Mol Cell; 2018 Aug; 71(4):554-566.e7. PubMed ID: 30078722 [TBL] [Abstract][Full Text] [Related]
18. Concurrent TMPRSS2-ERG and SLC45A3-ERG rearrangements plus PTEN loss are not found in low grade prostate cancer and define an aggressive tumor subset. Hernández S; Font-Tello A; Juanpere N; de Muga S; Lorenzo M; Salido M; Fumadó L; Serrano L; Cecchini L; Serrano S; Lloreta J Prostate; 2016 Jun; 76(9):854-65. PubMed ID: 26959281 [TBL] [Abstract][Full Text] [Related]
19. Cysteine-rich secretory protein-3 (CRISP3) is strongly up-regulated in prostate carcinomas with the TMPRSS2-ERG fusion gene. Ribeiro FR; Paulo P; Costa VL; Barros-Silva JD; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR PLoS One; 2011; 6(7):e22317. PubMed ID: 21814574 [TBL] [Abstract][Full Text] [Related]
20. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]